Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 3 5Phase 1 5Phase 4 2

Status

Completed 3Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Endocrine 5Gastrointestinal 3NET 2Lymphoid 1

Conditions

Pituitary Neoplasms 2Gastro-enteropancreatic neuroendocrine tumor 2Acromegaly 2Lymphoma, Follicular 1Growth Disorders 1Gigantism 1Carcinoid Tumor 1

Interventions

Everolimus 8lanreotide 7Octreotide 7lutetium Lu 177 dotatate 6pasireotide 5Thyrotropin Alfa 5Mitotane 4Etoposide 4Doxorubicin 4177Lu-octreotide, DOTA(0)-Tyr(3)- 4amino-acid, glucose, and electrolyte solution 3Mifepristone 3Filgrastim 3Corlux 3Cisplatin 3Chemotherapy, Adjuvant 3Capecitabine 3Cabergoline 3vandetanib 2telotristat ethyl 2surufatinib 2ribociclib 2fluorodopa F 18 2cabozantinib 2Temozolomide 2Receptor-Like Protein Tyrosine Phosphatases, Class 2 2Lutetium-177 2Lutetium 2Leucovorin 2Iodine-131 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 3 × pasireotide × Endocrine × Clear all
NCT06784752 2026-04-30

NETTER-3

Novartis

Phase 3 Recruiting
240 enrolled
EndocrineGastrointestinalLymphoidNET

Gastro-enteropancreatic neuroendocrine tumor, Lymphoma, Follicular

NCT03972488 2026-01-21

NETTER-2

Advanced Accelerator Applications

Phase 3 Active not recruiting
226 enrolled 14 charts
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

NCT02354508 2019-12-10

Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues

Novartis

Phase 3 Completed
123 enrolled 27 charts
Endocrine

Acromegaly, Gigantism, Growth Disorders, Pituitary Neoplasms

NCT01137682 2018-04-05

PAOLA

Novartis

Phase 3 Completed
198 enrolled 17 charts
Endocrine

Acromegaly, Pituitary Neoplasms

NCT00690430 2013-07-30

Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease

Novartis

Phase 3 Completed
186 enrolled 11 charts
Endocrine

Carcinoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡